Hit by copycat meds, Amgen trims 172 more jobs, this time in operations, R&D and sales

Amgen's top line has suffered from knockoff competition in recent quarters, and now the pain is moving to its payroll. After disclosing almost 150 cuts on the East Coast last week, the biotech giant now says it's cutting 172 staffers at its headquarters and in the field.